Ceribell (CBLL) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $28.1 million, a 33% increase year-over-year (YoY) from $21.2 million in Q2 2025 and a 6% sequential increase from Q1 2026.

Product Revenue: $21.2 million, up 33% YoY.

Subscription Revenue: $6.9 million, a 30% increase YoY.

Active Accounts: Increased by 32 to a total of 712 active accounts.

Gross Margin: 92%, benefiting from a $1.6 million tariff refund; 89% excluding this refund.

Operating Expenses: $45.9 million, a 37% increase YoY, driven by higher sales and marketing expenses and ongoing ITC litigation costs.

Net Loss: $19.3 million, or $0.51 per share, compared to a loss of $13.6 million, or $0.38 per share, in Q2 2025.

Adjusted EBITDA Loss: $9.8 million, slightly improved from a $10 million loss in Q2 2025.

Cash Position: $129 million as of June 30, 2026.

2Strategic Updates and Business Highlights

Growth Strategy: Continued focus on expanding the account base and deepening utilization within existing accounts, with a strong emphasis on clinical account management.

New Product Launches: Successful launch of Neonate and pediatric products, along with a commercial pilot for a delirium monitoring solution.

FDA Clearances: Received clearances for new algorithms targeting EEG artifact rejection and epileptiform abnormality detection, enhancing clinical utility.

Delirium Monitoring Solution: Positive early feedback from pilot programs and a favorable CMS NTAP ruling expected to boost adoption.

Market Positioning: Aiming to establish EEG as a new vital sign, with plans for a new hardware platform expected to launch in 2027.

3Forward Guidance and Outlook

2026 Revenue Guidance: Revised to $114 million to $117 million, reflecting 28% to 31% growth over 2025.

2027 Expectations: Anticipated acceleration in revenue growth driven by new product contributions, particularly from the Neonate and pediatric lines and the delirium solution.

4Challenges and Points of Concern

Operating Expenses: Continued increase in operating expenses, particularly due to litigation costs and stock-based compensation, may pressure profitability.

Net Loss: The company reported a larger net loss compared to the previous year, raising concerns about the sustainability of current spending levels.

Sales Force Maturation: While newer sales representatives are beginning to contribute, the full impact on revenue growth may take time as they progress through their productivity curves.

5Notable Q&A Insights

FDA Approvals Impact: Management indicated that new algorithm approvals are expected to enhance user engagement and utilization without increasing costs, potentially driving revenue growth in the future.

OpEx Management: CFO Scott Blumberg highlighted the need for careful management of operating expenses, with expectations for some reduction in litigation-related costs moving forward.

Delirium Solution Launch: The decision to launch the delirium monitoring solution in Q4 2026 was influenced by positive pilot feedback and favorable reimbursement conditions.

Regional Health Systems Strategy: The newly established strategic account management team is showing strong early momentum, with expectations for significant account additions in 2027. Overall, Ceribell demonstrated strong revenue growth and strategic advancements in Q2 2026, while also facing challenges related to operating expenses and net losses. The outlook for 2027 appears promising with new product launches and market expansion initiatives.